171 related articles for article (PubMed ID: 36477802)
1. HLA-E-restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD.
Vietzen H; Furlano PL; Cornelissen JJ; Böhmig GA; Jaksch P; Puchhammer-Stöckl E
Blood; 2023 Mar; 141(13):1560-1573. PubMed ID: 36477802
[TBL] [Abstract][Full Text] [Related]
2. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
Front Immunol; 2020; 11():1231. PubMed ID: 32625211
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory NKG2A
Vietzen H; Staber PB; Berger SM; Furlano PL; Kühner LM; Lubowitzki S; Pichler A; Strassl R; Cornelissen JJ; Puchhammer-Stöckl E
Front Immunol; 2023; 14():1183788. PubMed ID: 37426645
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
Sebelin-Wulf K; Nguyen TD; Oertel S; Papp-Vary M; Trappe RU; Schulzki A; Pezzutto A; Riess H; Subklewe M
Transpl Immunol; 2007 Apr; 17(3):203-10. PubMed ID: 17331848
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
[TBL] [Abstract][Full Text] [Related]
6. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
7. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
Riddler SA; Breinig MC; McKnight JL
Blood; 1994 Aug; 84(3):972-84. PubMed ID: 8043879
[TBL] [Abstract][Full Text] [Related]
8. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
Kinch A; Sundström C; Tufveson G; Glimelius I
Leuk Lymphoma; 2016 Oct; 57(10):2351-8. PubMed ID: 27104753
[TBL] [Abstract][Full Text] [Related]
9. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
Hu J; Yu YW; Han DS; Li XJ; Zhang YQ; Cai HL; Xiao YH; Zheng X
Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
[TBL] [Abstract][Full Text] [Related]
12. Lytic and latent EBV gene expression in transplant recipients with and without post-transplant lymphoproliferative disorder.
Kroll J; Li S; Levi M; Weinberg A
J Clin Virol; 2011 Nov; 52(3):231-5. PubMed ID: 21900040
[TBL] [Abstract][Full Text] [Related]
13. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Imadome KI; Mizukami Y; Okumura T
Medicine (Baltimore); 2022 Mar; 101(12):e29055. PubMed ID: 35357349
[TBL] [Abstract][Full Text] [Related]
14. Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
Lustberg ME; Pelletier RP; Porcu P; Martin SI; Quinion CD; Geyer SM; Caligiuri MA; Baiocchi RA
Transplantation; 2015 Jun; 99(6):1220-5. PubMed ID: 25427163
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of Epstein-Barr virus load and killer T cells in pediatric renal transplant recipients.
Sato T; Fujieda M; Maeda A; Tanaka E; Miyamura M; Chikamoto H; Hisano M; Akioka Y; Ishiura Y; Dohno S; Hattori M; Wakiguchi H
Clin Nephrol; 2008 Nov; 70(5):393-403. PubMed ID: 19000539
[TBL] [Abstract][Full Text] [Related]
17. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients.
Hopwood PA; Brooks L; Parratt R; Hunt BJ; Bokhari M; Thomas JA; Yacoub M; Crawford DH
Transplantation; 2002 Jul; 74(2):194-202. PubMed ID: 12151731
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
Quintero Bernabeu J; Juamperez J; Mercadal-Hally M; Larrarte King M; Gallego Melcon S; Gros Subias L; Sábado Álvarez C; Soler-Palacin P; Melendo Pérez S; Esperalba J; Navarro Jiménez A; Garrido Pontnou M; Camacho Soriano J; Hidalgo Llompart E; Bilbao Aguirre I; Charco Torra R
Pediatr Transplant; 2022 Sep; 26(6):e14292. PubMed ID: 35466492
[TBL] [Abstract][Full Text] [Related]
20. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Mentzer SJ; Perrine SP; Faller DV
Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
